Amgen is experiencing accelerated sales erosion for two major products, Prolia (sales down 32%) and XGEVA (sales down 34%), due to lower volume and pricing from new biosimilar competitors. This significant revenue loss creates pressure to optimize operations and find efficiencies to offset the financial impact.
Filing excerpt
The decreases in global Prolia sales for the three and six months ended June 30, 2026 were primarily driven by lower volume of 20% and 19%, respectively, and lower net selling price of 12% and 11%, respectively.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-10qmarketShareLossGet every 10-Q signal for Amgen and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/b804e52d-bfa7-4596-b587-08cbd141e543 returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.
{
"signal_id": "b804e52d-bfa7-4596-b587-08cbd141e543",
"signal_type": "sec-10q",
"signal_subtype": "marketShareLoss",
"detected_at": "2026-08-11T08:11:01.218+00:00",
"company": {
"name": "Amgen",
"domain": "amgen.com"
},
"data": {
"detail": "Amgen is experiencing accelerated sales erosion for two major products, Prolia (sales down 32%) and XGEVA (sales down 34%), due to lower volume and pricing from new biosimilar competitors. This significant revenue loss creates pressure to optimize operations and find efficiencies to offset the financial impact.",
"metrics": {
"pct": -32,
"timeframe": "current_quarter",
"pct_context": "Prolia total sales change YoY for the quarter",
"dollar_context": "Prolia quarterly sales decline YoY ($1,122M to $759M)",
"dollar_millions": 363
},
"summary": "Prolia and XGEVA sales plummet over 30% due to biosimilar competition after patent expiry.",
"excerpts": "The decreases in global Prolia sales for the three and six months ended June 30, 2026 were primarily driven by lower volume of 20% and 19%, respectively, and lower net selling price of 12% and 11%, respectively.",
"relevance": 0.9,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/amgn-20260630.htm",
"filing_date": "2026-08-04",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "06/30",
"sales_relevance": "Urgency to improve",
"signal_category": "market",
"regions_mentioned": [
"United States",
"ROW",
"Europe"
]
}
}
curl https://signals.autobound.ai/v1/signals/b804e52d-bfa7-4596-b587-08cbd141e543 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"amgen.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.